Jasper Therapeutics (JSPR) Accounts Payables (2019 - 2025)
Jasper Therapeutics (JSPR) posted quarterly Accounts Payables of $6.2 million for Q4 2025, up 54.46% year-over-year from $4.0 million in Q4 2024, and up 6120.0% quarter-over-quarter from $100000.0 in Q3 2025.
Jasper Therapeutics (JSPR) Accounts Payables (2019 - 2025) Analysis & Trends
Jasper Therapeutics' Accounts Payables history runs 7 years deep, the most recent figure standing at $6.2 million for Q4 2025.
- In Q4 2025, Accounts Payables rose 54.46% year-over-year to $6.2 million; the TTM figure through Dec 2025 stood at $6.2 million (up 54.46% YoY), while the FY2025 annual figure was $6.2 million, up 54.46% from the prior year.
- Accounts Payables for Q4 2025 stood at $6.2 million, up from $100000.0 in the prior quarter.
- The five-year high for Accounts Payables was $6.2 million in Q4 2025, with the low at $100000.0 in Q1 2024.
- The 5-year median for Accounts Payables is $3.0 million (2024), against an average of $2.4 million.
- The sharpest annual moves came in 2024 and 2025: Accounts Payables tumbled 97.4% in 2024, then surged 2895.0% in 2025.
- Jasper Therapeutics' Accounts Payables stood at $3.9 million in 2021, then sank by 54.89% to $1.8 million in 2022, then jumped by 134.67% to $4.1 million in 2023, then slipped by 2.94% to $4.0 million in 2024, then jumped by 54.46% to $6.2 million in 2025.
- Business Quant data shows JSPR's Accounts Payables at $6.2 million in Q4 2025, $100000.0 in Q3 2025, and $100000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Jasper Therapeutics | 20.08 Mn | 20.08 Mn | - | 2.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.22 Mn |
| Sep 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Mar 31, 2025 | 3.00 Mn |
| Dec 31, 2024 | 4.03 Mn |
| Sep 30, 2024 | 3.09 Mn |
| Jun 30, 2024 | 2.96 Mn |
| Mar 31, 2024 | 100,000.00 |
| Dec 31, 2023 | 4.15 Mn |
| Sep 30, 2023 | 3.26 Mn |
| Jun 30, 2023 | 1.58 Mn |
| Mar 31, 2023 | 3.85 Mn |
| Dec 31, 2022 | 1.77 Mn |
| Sep 30, 2022 | 3.12 Mn |
| Jun 30, 2022 | 3.00 Mn |
| Mar 31, 2022 | 1.15 Mn |
| Dec 31, 2021 | 3.92 Mn |
| Sep 30, 2021 | 2.25 Mn |
| Jun 30, 2021 | 328,928.00 |
| Mar 31, 2021 | 180,769.00 |